# A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

> **NCT04780685** · PHASE2 · UNKNOWN · sponsor: **Stemedica Cell Technologies, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** hMSC

## Key facts

- **NCT ID:** NCT04780685
- **Lead sponsor:** Stemedica Cell Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-20
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04780685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04780685, "A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04780685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*